WARSAW, Poland, Oct. 31, 2022 /PRNewswire/ -- Molecure S.A. ("Molecure") (WSE:MOC) a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases, announces third quarter results for the period ended 30 September 2022. The full report in Polish can be found here.
Read more at prnewswire.comMolecure Third Quarter 2022 Pipeline Highlights and Financial Results
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here